A new class of drugs for BNCT? Borylated derivatives of ferrocenium compounds in animal experiments

L. Weissfloch, M. Wagner, T. Probst, R. Senekowitsch-Schmidtke, K. Tempel, M. Molls

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

A new class of drugs, borylated derivatives of ferrocenium compounds, which show a comparatively facile synthesis is investigated on their boron neutron capture accumulation. Investigations focused on the fast and effective testing of 12 ferrocene derivatives with tetracoordinated boron atoms, which should accumulate in rodent tumors. The macroscopic studies on time-dependent boron distributions and boron concentrations in mice were carried out by inductively coupled plasma-atomic emission spectrometry, inductively coupled plasma-mass spectrometry, and quantitative neutron capture radiography. The determination of boron concentrations after injection of 2b showed high boron contents in spleen, liver, kidneys, less in lung and muscle, and poor in integral blood, blood plasma, tumor, and brain. It is interesting to note that 2b penetrates the blood-brain barrier which may be advantageous in the treatment of astrocytomas and glioblastomas.

Original languageEnglish
Pages (from-to)43-49
Number of pages7
JournalBioMetals
Volume14
Issue number1
DOIs
StatePublished - 2001
Externally publishedYes

Keywords

  • Boron neutron capture therapy (BNCT)
  • Cancer therapy
  • Ferrocene
  • Murine tumor models
  • Neurological toxicity

Fingerprint

Dive into the research topics of 'A new class of drugs for BNCT? Borylated derivatives of ferrocenium compounds in animal experiments'. Together they form a unique fingerprint.

Cite this